Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > PCSK9 > EP-103

PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair

For research use only.

Order Now

    Materials Provided
    96tests
    IDComponentsSize
    A006-214Human LDL R35μg
    A007-214Biotinylated Human PCSK910μg
    A003-214Streptavidin-HRP10μg
    PC9-NA003Anti-PCSK9 Neutralizing Antibody40μg
  • Product Overview
    PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair is based on a competition-ELISA method, is used to screening for inhibitors of human PCSK9 binding to human LDL R. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human PCSK9 to bind to human LDL R.
  • Reconstitution
    See Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    1. Unopened kit should be stored at -25~-15℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Materials Provided
    480tests
    IDComponentsSize
    A006-214Human LDL R160μg
    A007-214Biotinylated Human PCSK910μg
    A003-214Streptavidin-HRP10μg
    PC9-NA003Anti-PCSK9 Neutralizing Antibody200μg
Typical Data Please refer to DS document for the assay protocol.
 PCSK9 TYPICAL DATA

INHIBITION OF PCSK9 [BIOTINYLATED]: LDL R BINDING BY ANTI-PCSK9 NEUTRALIZING ANTIBODY
Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:6 Details
  • Number of Drugs in Clinical Trials:28 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message